Verrica (VRCA) Q1 2026 Earnings Transcript

Image source: The Motley Fool.

Date

Tuesday, May 12, 2026 astatine 8:30 a.m. ET

Call participants

• Chief Executive Officer — Jayson Rieger

• Chief Commercial Officer — Chris Chapman

• Chief Medical Officer — Noah Rosenberg

• Interim Chief Financial Officer — John Kirby

• Chief Operating Officer — David Zawitz

Need a punctuation from a Motley Fool analyst? Email [email protected]

Full Conference Call Transcript

Jayson Rieger: Thank you, Kevin. Good evening, everyone, and convey you for joining america connected our archetypal 4th 2026 firm update call. I americium pleased to study that successful the archetypal quarter, we saw accelerating maturation successful marketplace request for YCANTH, mounting caller records for dispensed applicator units during the 4th and successful the period of March. This maturation continued aft the extremity of the 4th arsenic we observed further accrued request successful April. YCANTH besides achieved different important milestone successful February arsenic our partner, Torii Pharmaceutical, launched YCANTH successful Japan for patients with molluscum pursuing their regulatory support past year.

Our anticipation is that Japan is lone the opening of our planetary enlargement efforts for YCANTH arsenic we are actively moving to grow the availability of YCANTH into caller markets astir the world. While we turn the YCANTH business, we're besides advancing our merchandise portfolio. As you whitethorn recall, successful January we announced that the archetypal diligent had been dosed successful our planetary Phase III programme for the attraction of communal warts, which represents a captious milestone successful our strategy to grow into caller indications.

I'm arrogant to denote that we person achieved much than 50% of the presently targeted enrollment successful the archetypal Phase III trial, besides known arsenic COVE-2, and person begun enrolling patients successful the semipermanent follow-up study, COVE-4 successful this program. Our people is to initiate the 2nd Phase III proceedings known arsenic COVE-3 successful this programme by mid-2026. We besides proceed to beforehand our Phase III-ready asset, VP-315, for the attraction of basal compartment carcinoma arsenic we've begun efforts to unafraid objective supplies and prime a CRO to enactment initiation of the Phase III program. VP-315 is garnering expanding attraction wrong the dermatology assemblage based connected compelling proof-of-concept information from our Phase II program.

I'll present supply a elaborate update connected our YCANTH commercialized business. In the archetypal 4th of 2026, we reported full gross of $5 million, including U.S. YCANTH merchandise gross of $4.3 million, which was up 25.4% implicit the archetypal 4th of 2025. First 4th U.S. YCANTH dispensed applicator units accrued to 15,302, increasing 51.3% implicit the archetypal 4th of 2025. On a sequential basis, U.S. YCANTH gross and dispensed applicator units accrued 15.3% and 12.1%, respectively, compared to the 4th fourth of 2025.